Glucotrack (GCTK) Capital Expenditures (2010 - 2025)

Glucotrack's (GCTK) quarterly Capital Expenditures came in at $20000.0 in Q4 2025, down 70.15% on a QoQ basis from $67000.0 in Q3 2025.

Glucotrack (GCTK) Capital Expenditures (2010 - 2025) Analysis & Trends

Glucotrack (GCTK) has 15 years of Capital Expenditures data on file, last reported at $20000.0 in Q4 2025.

Quarterly Capital Expenditures changed N/A year-over-year to $20000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $96000.0 (down 7.69% YoY) and the FY2025 annual result came in at $96000.0, down 7.69% from the prior year.
Capital Expenditures declined to $20000.0 in Q4 2025, from $67000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $67000.0 in Q3 2025 to a low of -$3000.0 in Q4 2022.
A 4-year average of $25125.0 and a median of $16000.0 in 2024 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2022 — Capital Expenditures plunged 175.0% — and 2025, when it jumped 103.03%.
Tracing GCTK's Capital Expenditures over 4 years: stood at $4000.0 in 2021, then sank by 175.0% to -$3000.0 in 2022, then soared by 1200.0% to $33000.0 in 2024, then slumped by 39.39% to $20000.0 in 2025.
The last three Capital Expenditures figures came in at $20000.0 (Q4 2025), $67000.0 (Q3 2025), and $9000.0 (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Intuitive Surgical	134.13 Bn	128.91 Bn	1.96 Bn	112.60 Mn
2	Becton Dickinson	52.76 Bn	51.90 Bn	2.32 Bn	143.00 Mn
3	Alcon	35.81 Bn	34.46 Bn	1.68 Bn	374.00 Mn
4	Resmed	33.72 Bn	32.25 Bn	861.22 Mn	51.13 Mn
5	Medline	29.38 Bn	26.70 Bn	2.22 Bn	111.00 Mn
6	West Pharmaceutical Services	25.00 Bn	24.57 Bn	329.20 Mn	43.20 Mn
7	Solventum	15.46 Bn	15.06 Bn	1.29 Bn	83.00 Mn
8	Cooper Companies	14.88 Bn	14.74 Bn	735.40 Mn	86.40 Mn
9	Baxter International	13.58 Bn	11.43 Bn	1.03 Bn	116.00 Mn
10	Glucotrack	1.68 Mn	553,542.53	-	-

Download Data